Genmab — Maj 2026
-
AMGEN Q1 2026 TEPEZZA
(teprotumumab-trbw) sales increased 29% year-over-year to $490 million in the first quarter, driven by a 22% impact from higher inventory levels and higher net selling price. https://www.amgen.com/newsroom/press-releases/2026/04/c-o-r-r-e-c-t-i-o-n----amgen -
The IPO Buzz: Hemab Therapeutics (COAG) Prices Upsized IPO at $18 – Top of Range https://www.iposcoop.com/the-ipo-buzz-hemab-therapeutics-coag-prices-upsized-ipo-at-18-top-of-range/#:~:text=Hemab Therapeutics (COAG) upsized its,night%2C April 30%2C 2026.
-
Jeg er ikke "subscriber", men kan da se, at de her stiller et (oplagt) spørgsmål til baggrunde for Genmabs sene udvidelse af Peto fase 3 https://www.oncologypipeline.com/apexonco/genmabs-unexpected-petosemtamab-expansion
-
OK udvikling - et run op mod RSI 60-70 (omkring kurs 1900) i Maj er helt realistisk https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/132180_GMAB_2026_05_05_12_49_57.png
-
here's RAINFOL-07 - New trial - Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer (RAINFOL
-07) https://clinicaltrials.gov/study/NCT07564141 -
God morgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind